Lumigan 0,3 mg/ml Eye Drops
PDF Leaflet Revision Date: 21 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension.
Dosage (summary)
One drop in affected eye(s) once daily in the evening.
Onset of Action / Duration
Onset: 4 hours, Duration: 24 hours
Special Populations
- Elderly population
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; use with caution in breastfeeding.
Key Drug Interactions
- Other prostaglandin analogues may reduce IOP-lowering effect
Contraindications
- Hypersensitivity to bimatoprost or excipients
Common side effects
- Conjunctival hyperaemia
- Ocular pruritus
- Eyelash growth
Counselling Points
- Avoid contact of dropper tip with eye
- Remove contact lenses before use
- Monitor for changes in eye appearance
Serious warnings
- Potential for permanent iris pigmentation
- Prostaglandin analogue periorbitopathy
Important Disclaimer
The Lumigan 0,3 mg/ml Eye Drops professional information leaflet below is the property of AbbVie and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
